Luis Pagan
General Practice · Dorado, PRNPI 1831155092
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,481 of the $5,736 with a category attached, or 95.6%. Eli Lilly accounts for 96.2% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $4,384, more than ten times the $100 reported in 2019. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $163.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6K
- Johnson & Johnson$100
- Novo Nordisk$94
- AbbVie$25
Across 61 payments — averaging $56,515 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$3.3M
- Eli Lilly$103K
- Boehringer Ingelheim International GmbH$672
What the payments were for
- Travel & lodging$5,48196%
- Food & beverage$2194%
- Education$361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 32 | $5,517 |
| Johnson & Johnson | 1 | $100 |
| Novo Nordisk | 1 | $94 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$100
How this compares
$5,736 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 27 | $1,369 |
| Haloperidol | 24 | $877 |
| Valproic AcidValproic Acid (As Sodium Salt) | 12 | $651 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 17 | $280 |
| Metformin Hcl | 53 | $262 |
| Rosuvastatin Calcium | 20 | $259 |
| Losartan Potassium | 34 | $236 |
| Glimepiride | 19 | $189 |
| Atorvastatin Calcium | 17 | $166 |
| Gabapentin | 18 | $162 |
| Metoprolol Succinate | 14 | $148 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 17 | $119 |
| Temazepam | 14 | $119 |
| Lisinopril | 26 | $117 |
| Tamsulosin Hcl | 17 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $25 | $1,36927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Dorado
- Wilfredo CuevasSan Lorenzo$530K
- Julio BacoMayaguez$268K
- Soria Diaz BaezPonce$192K
- Carlos RomanCanovanas$140K
- William E TorresSan Juan$86K
- Rafael Mendoza RodriguezPonce$77K
- Frank Perez NogueiraSan German$70K
- Vivian Tamayo AgraitSan Juan$64K
- William Soto AvilesToa Baja$63K
- Jessica RosarioSanturce$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.